Veeva Systems Inc. (NYSE:VEEV) SVP Jonathan Faddis Sells 3,598 Shares of Stock

Veeva Systems Inc. (NYSE:VEEV) SVP Jonathan Faddis sold 3,598 shares of Veeva Systems stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $207.42, for a total value of $746,297.16. Following the completion of the transaction, the senior vice president now owns 10,668 shares of the company’s stock, valued at approximately $2,212,756.56. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Veeva Systems Trading Down 0.6 %

VEEV opened at $199.18 on Thursday. The firm has a market cap of $32.13 billion, a price-to-earnings ratio of 61.86, a PEG ratio of 2.02 and a beta of 0.74. Veeva Systems Inc. has a 12 month low of $160.21 and a 12 month high of $236.90. The stock has a fifty day moving average price of $221.86 and a 200-day moving average price of $202.84.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings results on Thursday, February 29th. The technology company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.81 by $0.11. The firm had revenue of $630.62 million during the quarter, compared to analyst estimates of $620.75 million. Veeva Systems had a return on equity of 11.26% and a net margin of 22.24%. On average, equities research analysts forecast that Veeva Systems Inc. will post 4.11 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. OFI Invest Asset Management acquired a new position in Veeva Systems during the 3rd quarter valued at about $25,000. Operose Advisors LLC acquired a new position in Veeva Systems during the 3rd quarter valued at about $29,000. DSM Capital Partners LLC acquired a new position in Veeva Systems during the 4th quarter valued at about $29,000. Vermillion & White Wealth Management Group LLC acquired a new position in Veeva Systems during the 4th quarter valued at about $32,000. Finally, Resurgent Financial Advisors LLC acquired a new position in Veeva Systems during the 4th quarter valued at about $33,000. 88.20% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

VEEV has been the subject of a number of recent research reports. KeyCorp lifted their target price on Veeva Systems from $232.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, March 5th. Robert W. Baird boosted their price objective on Veeva Systems from $245.00 to $251.00 and gave the company an “outperform” rating in a report on Friday, March 1st. StockNews.com upgraded Veeva Systems from a “hold” rating to a “buy” rating in a report on Friday, April 12th. The Goldman Sachs Group boosted their price objective on Veeva Systems from $219.00 to $248.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, Raymond James restated an “outperform” rating and set a $260.00 price objective on shares of Veeva Systems in a report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Veeva Systems presently has an average rating of “Moderate Buy” and an average target price of $234.90.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.